Analyzing circulating tumor DNA (ctDNA) has revealed mechanisms of primary or acquired resistance to EGFR blockade, such as alterations in KRAS, NRAS, HER2, MET, ERBB2, EGFR-ECD, BRAF, and MAP2K1 (29, 30). Here, EGFR is linked to neoplasm.